Integra LifeSciences Launches Fin-Lock™ Glenoid
Integra LifeSciences launched the Integra® Fin-Lock™ Glenoid for the Titan™ Modular Shoulder System to address glenoid component loosening and failure in total shoulder arthroplasty. May 24, 2016
Interventional Spine Announces FDA Clearance of Lordotic Opticage™
Interventional Spine announced FDA clearance of the 80 Lumbar Lordotic Opticage™, an intervertebral body fusion device for use with autogenous bone graft in patients with degenerative disc disease. May 24, 2016
Active Implants Announces 1st Meniscus Replacement in SUN Clinical Trial
Active Implants announced the first meniscus replacement in the SUN (Safety Using NUsurface®) clinical trial for patients with persistent knee pain following medial meniscus surgery. May 23, 2016
NuVasive Announces U.S. Launch of AttraX® Putty
NuVasive announced the U.S. launch of AttraX® Putty, a synthetic bone graft for use in the posterior lateral spine. May 23, 2016
Implanet Receives FDA Clearance and CE Mark for Jazz Claw Implant
Implanet received FDA 510(k) clearance and CE Mark approval for the Jazz Claw®, a hybrid implant designed to treat degenerative spinal pathologies. May 23, 2016
JNJ’s Business Review Day Highlights Company Priorities and Restructuring
Johnson & Johnson/JNJ's business review day on May 18 filled some gaps in my understanding of the restructuring picture, but some holes remain. Here is what we learned, and what we don't know yet. May 23, 2016
Medacta Reports on Device Utilization
Results from a 421-patient study revealed a 97.75% survival rate at 5 years for Medacta’s AMIStem hip implant. AMIStem has been implanted >100,000 times, to date. May 19, 2016
Vertebral Technologies Launches InterGraft Biologics
Vertebral Technologies launched the InterGraft™ series of 100% DBM osteoinductive scaffolds. May 19, 2016
Medtronic Announces U.S. Launch of Spine Essentials
Medtronic commenced U.S. launch of Spine Essentials™, implants and instruments designed to lend efficiency to the most common cervical fusion procedures. May 19, 2016
New Bone Therapeutics Phase II Trial of ALLOB for Severe Osteoporosis
Bone Therapeutics is planning a Phase II trial with ALLOB® allogeneic bone cell therapy for the treatment of severe osteoporosis. May 19, 2016
